Pyrimidine synthesis has been recently discovered as a metabolic vulnerability and promising therapy target in KRAS/LKB1 mutant non-small-cell lung cancer and PTEN mutant cancer (34, 35). This evidence concerns the gene STK11 and non-small cell lung carcinoma.